Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03789968 · ClinicalTrials.gov registry record
The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients
A clinical trial, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 411
- Enrollment target
NCT03789968: Completed study, sponsored by Thomas Jefferson University.
NCT03789968 is a clinical trial that has completed, run by Thomas Jefferson University. The registered enrollment target is 411 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03789968 has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 411 participants
- Enrollment target
Study Summary
This study will assess changes in the incidence and severity of drug interactions before and after switching antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide-based regimens in treatment experienced patients living with HIV infection.
Primary Outcome
The primary endpoint is to measure the change in mean total drug interaction scores pre and post ART switch to a bictegravir/emtricitabine/tenofovir alafenamide-based regimen. The total drug interaction scores for each patient pre- and post-switch will be calculated using a drug interaction score developed for this study. The score is obtained when entering a patient's ART and concomitant medications (CM) into the University of Liverpool's HIV Drug Interaction Checker database \[21\]. Each ART-C
Interventions
- DRUG bictegravir/emtricitabine/tenofovir alafenamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2020-10-05 |
What the finished NCT03789968 record still lists
NCT03789968 is an observational study that tracks outcomes without assigning an intervention. The registered 411 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which bictegravir/emtricitabine/tenofovir alafenamide is the first listed.
NCT03789968 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03789968 about?
NCT03789968 is a clinical study titled "The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients". This study will assess changes in the incidence and severity of drug interactions before and after switching antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide-based regimens in treatment experienced patients living with HIV infection.
What is the current status of trial NCT03789968?
This trial is currently completed. The enrollment target is 411 participants. The study started on 2019-09-01. Estimated completion is 2020-10-05.
What interventions are being tested in trial NCT03789968?
The interventions under investigation include: bictegravir/emtricitabine/tenofovir alafenamide (DRUG).
Who is sponsoring clinical trial NCT03789968?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI